María E. Riveiro

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

Michela Boi, Eugenio Gaudio, Paola Bonetti et al. · Clinical Cancer Research · 2015 · 283 citations

Medicine, Oncology, Pharmacology +14

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

Marie-Magdelaine Coudé, Thorsten Braun, Jeannig Berrou et al. · Oncotarget · 2015 · 268 citations · Full text

Medicine, Oncology, Pharmacology +16

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

Anton G. Henssen, Kristina Althoff, Andrea Odersky et al. · Clinical Cancer Research · 2015 · 180 citations · Full text

Medicine, Cancer Biology, Oncology +12

Structural insights into hydroxycoumarin-induced apoptosis in U-937 cells

María E. Riveiro, Albertina G. Moglioni, Ramiro Vázquez et al. · Bioorganic & Medicinal Chemistry · 2007 · 172 citations

Life Sciences, Medicinal Chemistry, Pharmacology +14

OTX015 (MK‐8628), a novel BET inhibitor, displays <i>in vitro</i> and <i>in vivo</i> antitumor effects alone and in combination with conventional therapies in glioblastoma models

Caroline Berenguer‐Daizé, Lucile Astorgues‐Xerri, Elodie Odore et al. · International Journal of Cancer · 2016 · 151 citations · Full text

Medicine, Oncology, Pharmacology +14